Cargando…
Effects of a Nutritional Supplement (DìRelax(TM)) on Anxiety in Dogs in a Randomized Control Trial Design
SIMPLE SUMMARY: The effects of a nutraceutical product, DìRelax(TM), were tested in a cohort of anxious dogs by the C-BARQ questionnaire to assess the presence of problematic behaviors, and by the impossible task paradigm, an experimental procedure to explore dogs’ cognitive performance following an...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868118/ https://www.ncbi.nlm.nih.gov/pubmed/35203143 http://dx.doi.org/10.3390/ani12040435 |
Sumario: | SIMPLE SUMMARY: The effects of a nutraceutical product, DìRelax(TM), were tested in a cohort of anxious dogs by the C-BARQ questionnaire to assess the presence of problematic behaviors, and by the impossible task paradigm, an experimental procedure to explore dogs’ cognitive performance following an expectancy frustration. Hematological and biochemical analyses showed no adverse effects. The treatment with DìRelax(TM) showed a positive effect on the dog’s performances, with some of the behaviors appearing improved. The results suggested that DiRelax(TM) may have some ameliorative effect on the cognitive performances of anxious dogs. ABSTRACT: This study aimed to investigate the efficacy of DìRelax(TM), a nutraceutical formulated to reduce anxiety in dogs, using a randomized controlled trial (RCT) design. The C-BARQ questionnaire, some clinical investigations, and the impossible task test were performed in dogs before and after treatment. The C-BARQ questionnaire is particularly useful for assessing the frequency and severity of problematic behaviors. The impossible task paradigm provides insight into the decision-making processes in the realm of expectancy frustration. Results showed an ameliorative effect on the performances of treated dogs during the solvable phases, with a significant decrease in the time needed to solve the task. No behavioral difference was found between treated and untreated anxious dogs during the unsolvable phase. According to the results from the C-BARQ questionnaire, some of the behaviors appeared to improve. Clinical investigations, including a complete blood cell count and blood chemistry, showed no difference between groups, thus suggesting the safety of the product. In general, this study suggests that DìRelax(TM) can be safely administered with no adverse effects and can exercise a beneficial effect on anxious dogs by enhancing their cognitive abilities, but further studies should investigate the best method of administration. |
---|